Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma

Journal of Interferon and Cytokine Research

Volumn 35, Issue 4, 2015, Pages 281-291

  Yoo, Esther M ^a   Trinh, Kham R ^a   Tran, Danh ^a   Vasuthasawat, Alex ^a   Zhang, Juan ^a,b   Hoang, Bao ^a,c,d   Lichtenstein, Alan ^a,c,d   Morrison, Sherie L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 2; CASPASE 3; CASPASE 8; CASPASE 9; CD138 ANTIBODY ALPHA2 INTERFERON FUSION PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 1BETA CONVERTING ENZYME; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; INTERFERON; MONOCLONAL ANTIBODY; SYNDECAN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR VOLUME; U266 CELL LINE; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY;

MURINAE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; INTERFERONS; MICE; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; SYNDECAN-1;

EID: 84926454355     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0125     Document Type: Article

References (34)

1. Anderson KC. 2012. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30(4):445-452.
2. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. 2000. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 10(2):125-144.
3. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990.
4. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence J, Jr., Abraham RT. 1996. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15(19):5256-5267.
5. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M. 2006. Highresolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9(4):313-325.
6. Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, Semenzato G, Pizzolo G, Menestrina F. 1999. CD138/ syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 12(12):1101-1106.
7. Crowder C, Dahle O, Davis RE, Gabrielsen OS, Rudikoff S. 2005. PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105(3):1280-1287.
8. Drexler H, Matsuo Y. 2000. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemialymphoma. Leukemia 14(5):777-782.
9. Fritz E, Ludwig H. 2000. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 11(11):1427-1436.
10. Gomez-Benito M, Balsas P, Bosque A, Anel A, Marzo I, Naval J. 2005. Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells. FEBS Lett 579(27):6217-6222.
11. Hjortsberg L, Lindvall C, Corcoran M, Arulampalam V, Chan D, Thyrell L, Nordenskjold M, Grander D, Pokrovskaja K. 2007. Phosphoinositide 3-kinase regulates a subset of interferon-alpha-stimulated genes. Exp Cell Res 313(2):404-414.
12. Huang TH, Chintalacharuvu KR, Morrison SL. 2007. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol 179(10):6881-6888.
13. Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, Chaganti R, Dalla-Favera R. 1997. Deregulation of MUM1/ IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17(2):226-230.
14. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uze G, Schreiber G. 2006. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 26(5):1888-1897.
15. Jaks E, Gavutis M, Uze G, Martal J, Piehler J. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366(2):525-539.
16. Kalie E, Jaitin DA, Abramovich R, Schreiber G. 2007. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem 282(15):11602-11611.
17. Lamken P, Lata S, Gavutis M, Piehler J. 2004. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J Mol Biol 341(1):303-318.
18. Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S, Kwee I, Rinaldi A, Ronchetti D, Verdelli D. 2006. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 46(3):226-238.
19. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, Goldschmidt H, Jauch A, Reme T, Jourdan M. 2011. A highrisk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 96(4):574-582.
20. Panaretakis T, Hjortsberg L, Tamm KP, Bjorklund AC, Joseph B, Grander D. 2008. Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Mol Biol Cell 19(1):41-50.
21. Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y. 2004. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem 47(20):4897-4904.
22. Racki WJ, Covassin L, Brehm M, Pino S, Ignotz R, Dunn R, Laning J, Graves SK, Rossini AA, Shultz LD. 2010. NOD-scid IL2R gamma-null (NSG) mouse model of human skin transplantation and allograft rejection. Transplantation 89(5):527-536.
23. Ravetch JV, Kinet J-P. 1991. Fc receptors. Annu Rev Immunol 9(1):457-492.
24. Ridley R, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson R. 1993. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81(3):767-774.
25. Shaffer AL, Emre NCT, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H. 2008. IRF4 addiction in multiple myeloma. Nature 454(7201):226-231.
26. Shaffer AL, Emre NT, Romesser PB, Staudt LM. 2009. IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res 15(9):2954-2961.
27. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhorn S, Grander D. 2002. Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene 21(8):1251-1262.
28. Thyrell L, Hjortsberg L, Arulampalam V, Panaretakis T, Uhles S, Dagnell M, Zhivotovsky B, Leibiger I, Grander D, Pokrovskaja K. 2004. Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/ mammalian target of rapamycin signaling pathway. J Biol Chem 279(23):24152-24162.
29. Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL. 2013. Anti-CD20-interferon-alpha fusion protein therapy of murine B-cell lymphomas. J Immunother 36(5):305-318.
30. Verdelli D, Nobili L, Todoerti K, Intini D, Cosenza M, Civallero M, Bertacchini J, Deliliers GL, Sacchi S, Lombardi L, Neri A. 2009. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol Oncol 27(1):23-30.
31. Weiss K. 1998. Safety profile of interferon-alpha therapy. Semin Oncol 25(1 Suppl 1):9-13.
32. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM. 1996. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94(2):318-323.
33. Xuan C, Steward KK, Timmerman JM, Morrison SL. 2010. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115(14):2864-2871.
34. Yoshida S, Nakazawa N, Iida S, Hayami Y, Sato S, Wakita A, Shimizu S, Taniwaki M, Ueda R. 1999. Detection of MUM1/ IRF4-IgH fusion in multiple myeloma. Leukemia 13(11):1812-1816.